High-dose cytarabine (HD araC) in the treatment of leukemias: A review

Current Hematologic Malignancy Reports

Volumn 8, Issue 2, 2013, Pages 141-148

  Reese, Nicholas D ^a   Schiller, Gary J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myeloid leukemia; AML; araC; Cytosine arabinoside; HD araC; High dose cytarabine; Leukemia

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CLADRIBINE; CLOFARABINE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVOR; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; EYE TOXICITY; GENE MUTATION; HUMAN; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUROTOXICITY; PHARMACODYNAMICS; SKIN TOXICITY; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA;

EID: 84878762683     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0156-3     Document Type: Article

References (67)

1. Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place high-dose regiments. Ann Hematol. 1991;62(4):119-28.
2. Plagemann PGW, Marz R, Wohlhueter RM. Transport and metabolism of deoxycytidine and 1-β-D-Arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphyorylation, and regulation of trisphosphate synthesis. Cancer Res. 1978;38:978-89.
3. Ho DHW. Distribution of kinase and deaminase of 1-β-D- Arabinofuranosylcytosine in tissues of man and mouse. Cancer Res. 1973;33:2816-20.
4. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol. 1971;233(38):109-10.
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. N Engl J Med. 1994;331:896-3.
6. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987;47:3005-11.
7. Preisler HD, Rustum Y, Priore RL. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Eur J Cancer Clin Oncol. 1985;21(1):23-30.
8. Rustum YM, Raymakers RA. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther. 1992;56(3):307-21.
9. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype. Cancer Res. 1998;58:4173-9.
10. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524-36.
11. Cai J, Damaraju VL, Groulx N, et al. Two distinct molecular mechanisms underlying Cytarabine resistance in Human Leukemic Cells. Cancer Res. 2008;68:2349-57.
12. Lowenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. N Engl J Med. 1999;341:1051-62.
13. Champlin R, Gajewski J, Nimer S, et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol. 1990;8(7):1199-6.
14. Wolff SN, Marion J, Stein RS, et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood. 1985;65:1407-11.
15. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36.
16. • Grimwade D, Hills RK, Moorman AV. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65. This large series of AML patients treated in MRC trials establishes the prognosis for patients with infrequently occurring cytogenetic abnormalities. And can help to guide therapy choices for patients with these infrequent genetic aberattions.
17. Marcucci G, Mrozek K, Ruppert AS. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. J Clin Oncol. 2005;23(24):5705-17.
18. Schlenk RF, Döhner K, Krauter J, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med. 2008;358:1909-18.
19. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. JAMA. 2009;301(22):2349-61.
20. Schlenk RF, Benner A, Krauter J, et al. Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-50.
21. Byrd JC, Dodge RK, Carroll A. Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. J Clin Oncol. 1999;17(12):3767-75.
22. Byrd JC, Ruppert AS, Mrozek K. Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-94.
23. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117(8):2366-72.
24. Cairoli R, Beghini A, Grillo G. Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood. 2006;107(9):3463-8.
25. Schnittger S, Kohl TM, Haferlach T. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-9.
26. Care RS, Vale PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-7.
27. Farag SS, Ruppert AS, Mrozek K, et al. Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. J Clin Oncol. 2005;23(3):482-93.
28. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2001;118(7):1754-62.
29. Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4603-9.
30. Schiller GJ. Treatment of resistant disease. Leukemia. 1998;12(s1):s20-4.
31. Kurosawa S, Yamaguchi T, Miyawaki S, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica. 2010;95(11):1857-64.
32. Momparler RL. A Model for the Chemotherapy of Acute Leukemia with 1-β-D-Arabinofuranosylcytosine. Cancer Res. 1974;34:1775-87.
33. Rudnick SA, Cadman EC, Capizzi RL, et al. High-dose cytarabine (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189-93.
34. Herzig RH, Wolff SN, Lazarus HM, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62:361-9.
35. Early AP, Preisler HD, Slocum H, et al. A Pilot Study of High-Dose 1-β-D-Arabinofuranosylcytosine for Acute Leukemia and Refractory Lymphoma: Clinical Response and Pharmacology. Cancer Res. 1982;42:1587-4.
36. Kantarjian HM, Keating MJ, Walters RS, et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1998;6(2):232-8.
37. Wiernik PH, Banks PL, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2):313-9.
38. Herzig RH, Lazarus HM, Wolff SN, et al. High-Dose Cytosine Arabinoside Therapy With and Without Anthracycline Antibiotics for Remission Reinduction of Acute Nonlymphoblastic Leukemia. J Clin Oncol. 1985;3(7):992-6.
39. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11(1):116-24.
40. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87:256-64.
41. te Boekhorst PA, Lowenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia. 1994;89(9):1480-6.
42. Robak T, Wrezesien-Kus A, Lech-Maranda E, et al. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39(1-2):121-9.
43. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003;82:231-5.
44. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115-26.
45. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharamacol. 2005;55:361-8.
46. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res. 1996;56:3030-7.
47. • Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulaing factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Hematol. 2011;155:1822-9. Phase I/II study demonstrating clofarabine and HD araC and G-CSF is highly active in resistant disease and has activity regardless of age and cytogenetic risk.
48. • Tse E, Leung AYH, Sim J, et al. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol. 2011;90:1277-81. Small study demonstrating efficacy and safety of clofarabine with HD araC in treating resistant AML.
49. • Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapased or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. J Clin Oncol. 2011;29 (suppl;abstr 6503) Phase III trial demonstrates clofarabine and HD araC improves remission rates and event free survival in elderly patients with résistant AML. These three studies highlight a clofarabine + HD arac as an effective salvage regimen for many patients with resistant AML.
50. Chevallier P, Prebet T, Pigneux A, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia. 2010;24:467-9.
51. Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn. 2008;118:356-60.
52. Cortes J, O'Brien SM, Pierece S, et al. The value of High-Dose Systemic Chemotherapy and Intrathecal Therapy for Central Nervous System Prophylaxis in Different Risk Groups of Adult Acute Lymphoblastic Leukemia. Blood. 1995;86(6):2091-7.
53. Wolk RW, Masse SR, Conklin R, et al. The incidence of central nervous system leukemia in adults with acute leukemia. Cancer. 1974;33:863-9.
54. Stewart DJ, Keating MJ, McCredick KB, et al. Natural history of central nervous system acute leukemia in adults. Cancer. 1981;47(1):184-96.
55. Ho DHW, Frei III E. Clinical pharmacology of 1-β-D- Arabinofuranosylcytosine. Clin Pharmacol Ther. 1971;12:944-54.
56. Breithaupt H, Pralle H, Eckhardt T, et al. Clinical Results and Pharmacokinetics of High-Dose Cytosine Arabinoside (HD ARA-C). Cancer. 1982;50:1248-57.
57. Slevin ML, Piall EM, Aherne GW, et al. Effect of Dose and Schedule on Pharmacokinetics of High-Dose Cytosine Arabinoside in Plasma and Cerebrospinal Fluid. J Clin Oncol. 1983;1(9):546-51.
58. Frick J, Ritch PS, Hansen R, et al. Successful Treatment of Meningeal Leukemia Using Systemic High-Dose Cytosine Arabinoside. J Clinical Oncol. 1984;2(5):365-8.
59. Amadori S, Papa G, Avvisati G, et al. Sequential Combination of Systemic High-Dose Ara-C and Asparginase for the Treatment of Central Nervous System Leukemia and Lymphoma. J Clinical Oncol. 1984;2(2):98-101.
60. Morra E, Lazzarino M, Inverardi D, et al. Systemic High-Dose Ara-C for the Treatment of Meningeal Leukemia in Adult Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. J Clinical Oncol. 1986;4(4):1207-11.
61. te Loo DMWM. van der Does-van den Berg A, van Wering ER, et al. Prognostic Significance of Blasts in the Cerebrospinal Fluid Without Pleiocytosis or a Traumatic Lumbar Puncture in Children With Acute Lymphoblastic Leukemia: Experience of the Dutch Childhood Oncology Group. J Clinical Oncol. 2006;24(15):2332-6.
62. Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96:3381-4.
63. Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood. 1992;80:2977-82.
64. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-42.
65. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. New Eng J Med. 2010;362:2380-8.
66. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial - INTACT 2. J Clin Oncol. 2004;22(5):785-94.
67. Herbst RS, Prager D, Hermann K, et al. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2005;23(25):5892-9.